Tischa J. M. van der Cammen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Tischa J. M. van der Cammen has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Nathalie van der Velde
Department of Internal Medicine, Section of Geriatric Medicine, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands
15 shared publications Ed F. van Beeck
Public Health Erasmus MC University Medical Center Rotterdam Rotterdam The Netherlands
10 shared publicationsPeter Patka
Department of Emergency Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
7 shared publications- Carolyn Shanty Sterke
Research Centre Innovations in Care, Rotterdam University of Applied Sciences, Rotterdam, The Netherlands
5 shared publications Caspar W. N. Looman
Department of Public Health, Erasmus University Medical Center, Rotterdam, the Netherlands
5 shared publicationsKlaas A. Hartholt
Section of Geriatric Medicine, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands
5 shared publications
Latest Publications
- Open Access
- 4 November 2016
- Published by Springer Nature in BMC Geriatrics
- Vol. 16 (1) , 1-10
Cost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial
The use of Fall-Risk-Increasing-Drugs (FRIDs) has been associated with increased risk of falls and associated injuries. This study investigates the effect of withdrawal of FRIDs versus ‘care as usual’ on health-related quality of life (HRQoL), costs, and cost-utility in community-dwelling older fallers. In a prospective multicenter randomized controlled trial FRIDs assessment combined with FRIDs-withdrawal or modification was compared with ‘care as usual’ in older persons, who visited the emergency department after experiencing a fall. For the calculation of costs the direct medical costs (intramural and extramural) and indirect costs (travel costs) were collected for a 12 month period. HRQoL was measured at baseline and at 12 months follow-up using the EuroQol-5D and Short Form-12 version 2. The change in EuroQol-5D and Short Form-12 scores over 12 months follow-up within the control and intervention groups was compared using the Wilcoxon Signed Rank test for continuous variables and the McNemar test for dichotomous variables. The change in scores between the control and intervention groups were compared using a two-way analysis of variance. We included 612 older persons who visited an emergency department because of a fall. The mean cost of the FRIDs intervention was €120 per patient. The total fall-related healthcare costs (without the intervention costs) did not differ significantly between the intervention group and the control group (€2204 versus €2285). However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant. Furthermore, the control group had a greater decline in EuroQol-5D utility score during the 12-months follow-up than the intervention group (p = 0.02). The change in the Short Form-12 Physical Component Summary and Mental Component Summary scores did not differ significantly between the two groups. Withdrawal of FRID’s in older persons who visited an emergency department due to a fall, did not lead to reduction of total health-care costs. However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant in combination with less decline in HRQoL is an important result. The trial is registered in the Netherlands Trial Register ( NTR1593 – October 1st 2008).
- 4 November 2016
- Published by Springer Nature in BMC Geriatrics
- Vol. 16 (1) , 1-10
Open AccessCost-utility of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of FALLs (IMPROveFALL) trial
The use of Fall-Risk-Increasing-Drugs (FRIDs) has been associated with increased risk of falls and associated injuries. This study investigates the effect of withdrawal of FRIDs versus ‘care as usual’ on health-related quality of life (HRQoL), costs, and cost-utility in community-dwelling older fallers. In a prospective multicenter randomized controlled trial FRIDs assessment combined with FRIDs-withdrawal or modification was compared with ‘care as usual’ in older persons, who visited the emergency department after experiencing a fall. For the calculation of costs the direct medical costs (intramural and extramural) and indirect costs (travel costs) were collected for a 12 month period. HRQoL was measured at baseline and at 12 months follow-up using the EuroQol-5D and Short Form-12 version 2. The change in EuroQol-5D and Short Form-12 scores over 12 months follow-up within the control and intervention groups was compared using the Wilcoxon Signed Rank test for continuous variables and the McNemar test for dichotomous variables. The change in scores between the control and intervention groups were compared using a two-way analysis of variance. We included 612 older persons who visited an emergency department because of a fall. The mean cost of the FRIDs intervention was €120 per patient. The total fall-related healthcare costs (without the intervention costs) did not differ significantly between the intervention group and the control group (€2204 versus €2285). However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant. Furthermore, the control group had a greater decline in EuroQol-5D utility score during the 12-months follow-up than the intervention group (p = 0.02). The change in the Short Form-12 Physical Component Summary and Mental Component Summary scores did not differ significantly between the two groups. Withdrawal of FRID’s in older persons who visited an emergency department due to a fall, did not lead to reduction of total health-care costs. However, the withdrawal of FRIDs reduced medication costs with a mean of €38 per participant in combination with less decline in HRQoL is an important result. The trial is registered in the Netherlands Trial Register ( NTR1593 – October 1st 2008).
- Open Access
- 10 September 2016
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 46 (1) , 142-146
Effectiveness of medication withdrawal in older fallers: results from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial
To investigate the effect of withdrawal of fall-risk-increasing-drugs (FRIDs) versus ‘care as usual’ on reducing falls in community-dwelling older fallers. randomised multicentre trial. six hundred and twelve older adults who visited an Emergency Department (ED) because of a fall. withdrawal of FRIDs. primary outcome was time to the first self-reported fall. Secondary outcomes were time to the second self-reported fall and to falls requiring a general practitioner (GP)-consultation or ED-visit. Intention-to-treat (primary) and a per-protocol (secondary) analysis were conducted. The hazard ratios (HRs) for time-to-fall were calculated using a Cox-regression model. Differences in cumulative incidence of falls were analysed using Poisson regression. during 12 months follow-up, 91 (34%) control and 115 (37%) intervention participants experienced a fall; 35% of all attempted interventions were unsuccessful, either due to recurrence of the initial indication for prescribing, additional medication for newly diagnosed conditions or non-compliance. Compared to baseline, the overall percentage of users of ≥3 FRIDs at 12 months did not change in either the intervention or the control group. Our intervention did not have a significant effect on time to first fall (HR 1.17; 95% confidence interval 0.89–1.54), time to second fall (1.19; 0.78–1.82), time to first fall-related GP-consultation (0.66; 0.42–1.06) or time to first fall-related ED-visit (0.85; 0.43–1.68). in this population of complex multimorbid patients visiting an ED because of a fall, our single intervention of FRIDs-withdrawal was not effective in reducing falls. Netherlands Trial Register NTR1593.
- 10 September 2016
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 46 (1) , 142-146
Open AccessEffectiveness of medication withdrawal in older fallers: results from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) trial
To investigate the effect of withdrawal of fall-risk-increasing-drugs (FRIDs) versus ‘care as usual’ on reducing falls in community-dwelling older fallers. randomised multicentre trial. six hundred and twelve older adults who visited an Emergency Department (ED) because of a fall. withdrawal of FRIDs. primary outcome was time to the first self-reported fall. Secondary outcomes were time to the second self-reported fall and to falls requiring a general practitioner (GP)-consultation or ED-visit. Intention-to-treat (primary) and a per-protocol (secondary) analysis were conducted. The hazard ratios (HRs) for time-to-fall were calculated using a Cox-regression model. Differences in cumulative incidence of falls were analysed using Poisson regression. during 12 months follow-up, 91 (34%) control and 115 (37%) intervention participants experienced a fall; 35% of all attempted interventions were unsuccessful, either due to recurrence of the initial indication for prescribing, additional medication for newly diagnosed conditions or non-compliance. Compared to baseline, the overall percentage of users of ≥3 FRIDs at 12 months did not change in either the intervention or the control group. Our intervention did not have a significant effect on time to first fall (HR 1.17; 95% confidence interval 0.89–1.54), time to second fall (1.19; 0.78–1.82), time to first fall-related GP-consultation (0.66; 0.42–1.06) or time to first fall-related ED-visit (0.85; 0.43–1.68). in this population of complex multimorbid patients visiting an ED because of a fall, our single intervention of FRIDs-withdrawal was not effective in reducing falls. Netherlands Trial Register NTR1593.
- Open Access
- 31 March 2016
- Published by MDPI AG in Geriatrics
- Vol. 1 (2) , 10
Potential Influence of Aspirin on Neopterin and Tryptophan Levels in Patients with a Delirium
In an in vitro study, it was found that aspirin might decrease neopterin production and tryptophan degradation. The aim of the present study was to evaluate the possible association between aspirin use and mean neopterin and tryptophan levels in patients with and without a delirium and whether the use of aspirin is associated with a decreased prevalence of delirium. Neopterin and tryptophan levels were determined previously in acutely ill admitted patients aged ≥65 years. The possible influence of aspirin on mean levels of neopterin and tryptophan was investigated with univariate analysis of variance in adjusted models. Eighty-three patients were included; 22 had a delirium. In patients without a delirium (no aspirin (n = 31) versus aspirin (n = 27)), mean neopterin levels were 47.0 nmol/L versus 43.6 nmol/L (p = 0.645) and tryptophan levels were 33.1 µmol/L versus 33.9 µmol/L (p = 0.816). In patients with a delirium (no aspirin (n = 13) versus aspirin (n = 9)), mean neopterin levels were 77.8 nmol/L versus 71.1 nmol/L (p = 0.779) and tryptophan levels were 22.4 µmol/L versus 27.3 µmol/L (p = 0.439). No difference was found in the distribution of aspirin users between patients with and without a delirium. In this study, we found that the use of aspirin had no significant effect on mean levels of neopterin and tryptophan. However, the raw data suggest that there might be a potential influence in patients with a delirium. Aspirin use was not associated with a decreased prevalence of delirium.
- 31 March 2016
- Published by MDPI AG in Geriatrics
- Vol. 1 (2) , 10
Open AccessPotential Influence of Aspirin on Neopterin and Tryptophan Levels in Patients with a Delirium
In an in vitro study, it was found that aspirin might decrease neopterin production and tryptophan degradation. The aim of the present study was to evaluate the possible association between aspirin use and mean neopterin and tryptophan levels in patients with and without a delirium and whether the use of aspirin is associated with a decreased prevalence of delirium. Neopterin and tryptophan levels were determined previously in acutely ill admitted patients aged ≥65 years. The possible influence of aspirin on mean levels of neopterin and tryptophan was investigated with univariate analysis of variance in adjusted models. Eighty-three patients were included; 22 had a delirium. In patients without a delirium (no aspirin (n = 31) versus aspirin (n = 27)), mean neopterin levels were 47.0 nmol/L versus 43.6 nmol/L (p = 0.645) and tryptophan levels were 33.1 µmol/L versus 33.9 µmol/L (p = 0.816). In patients with a delirium (no aspirin (n = 13) versus aspirin (n = 9)), mean neopterin levels were 77.8 nmol/L versus 71.1 nmol/L (p = 0.779) and tryptophan levels were 22.4 µmol/L versus 27.3 µmol/L (p = 0.439). No difference was found in the distribution of aspirin users between patients with and without a delirium. In this study, we found that the use of aspirin had no significant effect on mean levels of neopterin and tryptophan. However, the raw data suggest that there might be a potential influence in patients with a delirium. Aspirin use was not associated with a decreased prevalence of delirium.
- Open Access
- 1 January 2016
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 20 (1) , 77-81
Association of proton pump inhibitor use with recurrent falls and risk of fractures in older women: A study of medication use in older fallers
- 1 January 2016
- Published by Elsevier in The Journal of nutrition, health and aging
- Vol. 20 (1) , 77-81
Open AccessAssociation of proton pump inhibitor use with recurrent falls and risk of fractures in older women: A study of medication use in older fallers
- 15 April 2014
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 15 (3) , 350-355
Physical performance and quality of life in single and recurrent fallers: Data from the Improving Medication Prescribing to Reduce Risk of Falls study
Aim: Although guidelines regarding falls prevention make a clear distinction between single and recurrent fallers, differences in functional status, physical performance, and quality of life in single and recurrent fallers have not been thoroughly investigated. Therefore, we investigated the differences in functional status, physical performance and health‐related quality of life (HRQoL) between single and recurrent fallers.Methods: From October 2008 to October 2011, 616 community‐dwelling older adults who visited the emergency department as a result of a fall were enrolled. Physical performance was assessed with the Timed Up & Go (TUG) test, the Five Times Sit to Stand (FTSS) test, handgrip strength and the tandem stand test. Functional status was measured using the activities of daily living and instrumental activities of daily living scales. HRQoL was measured using the European Quality of Life five dimensions (EQ‐5D), and the Short Form‐12 version 2. A general linear model was used to compare the means of the scores.Results: Recurrent falls in community‐dwelling older adults were associated with poorer physical performance as measured by the TUG test (P < 0.001), FTSS test (P = 0.011), handgrip strength (P < 0.001) and tandem stand (P < 0.001), and lower HRQoL scores as measured by the EQ‐5D (P = 0.006) and SF‐12 (P = 0.006 and P = 0.012).Conclusion: The present findings provide further evidence that recurrent fallers have poorer physical performance and quality of life than single fallers. Recurrent falls might be a symptom of underlying disease and frailty, and reason for further assessment. Geriatr Gerontol Int 2015; 15: 350–355.
- 15 April 2014
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 15 (3) , 350-355
Physical performance and quality of life in single and recurrent fallers: Data from the Improving Medication Prescribing to Reduce Risk of Falls study
Aim: Although guidelines regarding falls prevention make a clear distinction between single and recurrent fallers, differences in functional status, physical performance, and quality of life in single and recurrent fallers have not been thoroughly investigated. Therefore, we investigated the differences in functional status, physical performance and health‐related quality of life (HRQoL) between single and recurrent fallers.Methods: From October 2008 to October 2011, 616 community‐dwelling older adults who visited the emergency department as a result of a fall were enrolled. Physical performance was assessed with the Timed Up & Go (TUG) test, the Five Times Sit to Stand (FTSS) test, handgrip strength and the tandem stand test. Functional status was measured using the activities of daily living and instrumental activities of daily living scales. HRQoL was measured using the European Quality of Life five dimensions (EQ‐5D), and the Short Form‐12 version 2. A general linear model was used to compare the means of the scores.Results: Recurrent falls in community‐dwelling older adults were associated with poorer physical performance as measured by the TUG test (P < 0.001), FTSS test (P = 0.011), handgrip strength (P < 0.001) and tandem stand (P < 0.001), and lower HRQoL scores as measured by the EQ‐5D (P = 0.006) and SF‐12 (P = 0.006 and P = 0.012).Conclusion: The present findings provide further evidence that recurrent fallers have poorer physical performance and quality of life than single fallers. Recurrent falls might be a symptom of underlying disease and frailty, and reason for further assessment. Geriatr Gerontol Int 2015; 15: 350–355.
- Open Access
- 12 November 2013
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 43 (1) , 20-25
Drug cessation in complex older adults: time for action
Background: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-of-life situations. To date, little information about the effects of drug cessation in these four situations is available. Objectives: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-life situations, we reviewed cessation of inappropriate drug use. Methods: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impairment; or cessation of inappropriate drug use in end-of-life situations. Results: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk. Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life. Conclusion: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psychotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.
- 12 November 2013
- Published by Oxford University Press (OUP) in Age and Ageing
- Vol. 43 (1) , 20-25
Open AccessDrug cessation in complex older adults: time for action
Background: general opinion is growing that drug cessation in complex older patients is warranted in certain situations. From a clinical viewpoint, drug cessation seems most warranted in four situations, i.e., falls, delirium, cognitive impairment and end-of-life situations. To date, little information about the effects of drug cessation in these four situations is available. Objectives: to identify the effects and effectiveness of drug cessation on falls, delirium and cognitive impairment. For end-of-life situations, we reviewed cessation of inappropriate drug use. Methods: electronic databases were searched using MeSH terms and relevant keywords. Studies published in English were included if they evaluated the effects of drug cessation in older persons, aged ≥65 years, with falls, delirium or cognitive impairment; or cessation of inappropriate drug use in end-of-life situations. Results: we selected seven articles for falls, none for delirium, two for cognition and two for end-of-life situations. Withdrawal of psychotropics reduced fall rate; a prescribing modification programme for primary care physicians reduced fall risk. Withdrawal of psychotropics and a systematic reduction of polypharmacy resulted in an improvement of cognition. Very little rigorous research has been conducted on reducing inappropriate medications in patients approaching end of life. Conclusion: little research has focussed on drug cessation. Available studies showed a beneficial impact of cessation of psychotropic drugs on falls and cognitive status. More research in this field is needed. The issue of systematic drug withdrawal in end-of-life cases is controversial, but is increasingly relevant in the face of rising numbers of older people of this clinical status.
- 1 October 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (11) , 1948-1952
Vitamin D and Physical Performance in Older Men and Women Visiting the Emergency Department Because of a Fall: Data from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) Study
Objectives: To investigate whether serum 25‐hydroxy vitamin D (25( OH ) D ) is associated with physical performance in men and women. Design: Cross‐sectional. Setting: Emergency departments ( ED s) of five hospitals. Participants: Older adults who visited an ED because of a fall (N = 616). Measurements: Physical performance was assessed using the T imed U p and G o T est, the F ive T ime S it to S tand T est, handgrip strength, and the tandem stand test. Multivariate linear regression was used to assess the association between physical performance and log‐transformed 25( OH ) D concentration adjusted for potential confounders. Results: In men, higher serum 25( OH ) D concentration was significantly associated with better handgrip strength (regression coefficient ( B ) = 3.86, 95% confidence interval ( CI ) = 2.04−5.69), faster TUG time ( B = −2.82, 95% CI = −4.91 to −0.73), and faster FTSS time ( B = −3.39, 95% CI = −5.67 to −1.11). In women, higher serum 25( OH ) D concentration was significantly associated with faster TUG time ( B = −2.68, 95% CI = −4.87 to −0.49). Conclusion: A positive association was found between serum 25( OH ) D level and physical performance in men and women. Intervention studies are needed of vitamin D –deficient older men and women to further investigate the effect of vitamin D supplementation in this group.
- 1 October 2013
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 61 (11) , 1948-1952
Vitamin D and Physical Performance in Older Men and Women Visiting the Emergency Department Because of a Fall: Data from the Improving Medication Prescribing to reduce Risk Of FALLs (IMPROveFALL) Study
Objectives: To investigate whether serum 25‐hydroxy vitamin D (25( OH ) D ) is associated with physical performance in men and women. Design: Cross‐sectional. Setting: Emergency departments ( ED s) of five hospitals. Participants: Older adults who visited an ED because of a fall (N = 616). Measurements: Physical performance was assessed using the T imed U p and G o T est, the F ive T ime S it to S tand T est, handgrip strength, and the tandem stand test. Multivariate linear regression was used to assess the association between physical performance and log‐transformed 25( OH ) D concentration adjusted for potential confounders. Results: In men, higher serum 25( OH ) D concentration was significantly associated with better handgrip strength (regression coefficient ( B ) = 3.86, 95% confidence interval ( CI ) = 2.04−5.69), faster TUG time ( B = −2.82, 95% CI = −4.91 to −0.73), and faster FTSS time ( B = −3.39, 95% CI = −5.67 to −1.11). In women, higher serum 25( OH ) D concentration was significantly associated with faster TUG time ( B = −2.68, 95% CI = −4.87 to −0.49). Conclusion: A positive association was found between serum 25( OH ) D level and physical performance in men and women. Intervention studies are needed of vitamin D –deficient older men and women to further investigate the effect of vitamin D supplementation in this group.
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 947-955
New Insights: Dose‐Response Relationship Between Psychotropic Drugs and Falls: A Study in Nursing Home Residents With Dementia
The contribution of specific psychotropic drugs to fall risk in patients with dementia has not been quantified precisely until now. The authors evaluated the dose‐response relationship between psychotropic drugs and falls in nursing home residents with dementia. Daily drug use and daily falls were recorded in 248 nursing home residents with dementia from January 1, 2006, to January 1, 2008. For each day of the study period, data on drug use were abstracted from the prescription database, and falls were retrieved from a standardized incident report system, resulting in a data set of 85 074 person‐days. The authors found significant dose‐response relationships for the use of antipsychotics (hazard ratio [HR], 2.78; 95% confidence interval [CI], 1.49–5.17), anxiolytics (1.60; 1.20–2.14), hypnotics and sedatives (2.58; 1.42–4.68), and antidepressants (2.84; 1.93–4.16). Fall risk increased significantly with 28% at 0.25 of the defined daily dose (DDD) of an antipsychotic or antidepressant, with 8% at 0.2 of the DDD of an anxiolytic, and with 56% at 0.5 of the DDD of a hypnotic or sedative; it increased further with dose increments and with combinations of psychotropics. Even at low dosages, psychotropic drugs are associated with increased fall risk in nursing home residents with dementia.
- 1 June 2012
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 52 (6) , 947-955
New Insights: Dose‐Response Relationship Between Psychotropic Drugs and Falls: A Study in Nursing Home Residents With Dementia
The contribution of specific psychotropic drugs to fall risk in patients with dementia has not been quantified precisely until now. The authors evaluated the dose‐response relationship between psychotropic drugs and falls in nursing home residents with dementia. Daily drug use and daily falls were recorded in 248 nursing home residents with dementia from January 1, 2006, to January 1, 2008. For each day of the study period, data on drug use were abstracted from the prescription database, and falls were retrieved from a standardized incident report system, resulting in a data set of 85 074 person‐days. The authors found significant dose‐response relationships for the use of antipsychotics (hazard ratio [HR], 2.78; 95% confidence interval [CI], 1.49–5.17), anxiolytics (1.60; 1.20–2.14), hypnotics and sedatives (2.58; 1.42–4.68), and antidepressants (2.84; 1.93–4.16). Fall risk increased significantly with 28% at 0.25 of the defined daily dose (DDD) of an antipsychotic or antidepressant, with 8% at 0.2 of the DDD of an anxiolytic, and with 56% at 0.5 of the DDD of a hypnotic or sedative; it increased further with dose increments and with combinations of psychotropics. Even at low dosages, psychotropic drugs are associated with increased fall risk in nursing home residents with dementia.
- 1 May 2012
- Published by American Public Health Association in American Journal of Public Health
- Vol. 102 (S2) , S207-S211
End of the Spectacular Decrease in Fall-Related Mortality Rate: Men Are Catching Up
Objectives. We determined time trends in numbers and rates of fall-related mortality in an aging population, for men and women. Methods. We performed secular trend analysis of fall-related deaths in the older Dutch population (persons aged 65 years or older) from 1969 to 2008, using the national Official-Cause-of-Death-Statistics. Results. Between 1969 and 2008, the age-adjusted fall-related mortality rate decreased from 202.1 to 66.7 per 100 000 older persons (decrease of 67%). However, the annual percentage change (change per year) in mortality rates was not constant, and could be divided into 3 phases: (1) a rapid decrease until the mid-1980s (men −4.1%; 95% confidence interval [CI] = −4.9, −3.2; women −6.5%; 95% CI, −7.1, −5.9), (2) flattening of the decrease until the mid-1990s (men −1.4%; 95% CI = −2.4, −0.4; women −2.0%; 95% CI = −3.4, −0.6), and (3) stable mortality rates for women (0.0%; 95% CI = −1.2, 1.3) and rising rates for men (1.9%; 95% CI = 0.6, 3.2) over the last decade. Conclusions. The spectacular decrease in fall-related mortality ended in the mid-1990s and is currently increasing in older men at similar rates to those seen in women. Because of the aging society, absolute numbers in fall-related deaths are increasing rapidly.
- 1 May 2012
- Published by American Public Health Association in American Journal of Public Health
- Vol. 102 (S2) , S207-S211
End of the Spectacular Decrease in Fall-Related Mortality Rate: Men Are Catching Up
Objectives. We determined time trends in numbers and rates of fall-related mortality in an aging population, for men and women. Methods. We performed secular trend analysis of fall-related deaths in the older Dutch population (persons aged 65 years or older) from 1969 to 2008, using the national Official-Cause-of-Death-Statistics. Results. Between 1969 and 2008, the age-adjusted fall-related mortality rate decreased from 202.1 to 66.7 per 100 000 older persons (decrease of 67%). However, the annual percentage change (change per year) in mortality rates was not constant, and could be divided into 3 phases: (1) a rapid decrease until the mid-1980s (men −4.1%; 95% confidence interval [CI] = −4.9, −3.2; women −6.5%; 95% CI, −7.1, −5.9), (2) flattening of the decrease until the mid-1990s (men −1.4%; 95% CI = −2.4, −0.4; women −2.0%; 95% CI = −3.4, −0.6), and (3) stable mortality rates for women (0.0%; 95% CI = −1.2, 1.3) and rising rates for men (1.9%; 95% CI = 0.6, 3.2) over the last decade. Conclusions. The spectacular decrease in fall-related mortality ended in the mid-1990s and is currently increasing in older men at similar rates to those seen in women. Because of the aging society, absolute numbers in fall-related deaths are increasing rapidly.
- 28 January 2012
- Published by Elsevier in Experimental Gerontology
- Vol. 47 (4) , 342-345
Why older people refuse to participate in falls prevention trials: A qualitative study
- 28 January 2012
- Published by Elsevier in Experimental Gerontology
- Vol. 47 (4) , 342-345
Why older people refuse to participate in falls prevention trials: A qualitative study